UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer
These data demonstrate that CDK4/6is are an effective and safe treatment for metastatic HR+/HER2- breast cancer. Efficacy was in line with trial data and other real-world data. DR was associated with improved PFS and OS, suggesting that trials of CDK4/6is at a lower starting dose are warranted.
Authors
- Wendy K. Thomas (ORCID: https://orcid.org/0009-0000-6439-9549)
- E. Daniels
- H. Reed (ORCID: https://orcid.org/0000-0002-5004-3397)
- Carol A. Atkinson (ORCID: https://orcid.org/0000-0002-3795-7442)
- S. Spensley (ORCID: https://orcid.org/0009-0001-1802-5957)
- António Alves (ORCID: https://orcid.org/0000-0002-4142-8308)
- S. Park (ORCID: https://orcid.org/0009-0003-4092-585X)
- Seamus Cook (ORCID: https://orcid.org/0000-0003-4596-1916)
- J. Helbrow (ORCID: https://orcid.org/0000-0003-3865-3966)
- M Beresford
- A. Halstead
- G. Gullick
- Nathalie Webber (ORCID: https://orcid.org/0000-0002-3526-1759)
- E. B. Nye (ORCID: https://orcid.org/0000-0002-4703-625X)
- Sonya Chew (ORCID: https://orcid.org/0000-0003-1306-0822)
- Rebecca Bowen (ORCID: https://orcid.org/0000-0002-1169-6125)
- Cindy K. Blair (ORCID: https://orcid.org/0000-0001-6698-678X)
- Richard A. Squires (ORCID: https://orcid.org/0000-0002-9887-3357)
- Tim Robinson (ORCID: https://orcid.org/0000-0003-0933-646X)
- William J. Watkins (ORCID: https://orcid.org/0000-0003-3262-6588)
- C.N. Owen
- E. K. Weir (ORCID: https://orcid.org/0009-0006-4219-6023)
- F. Aquilina
Institutions
- Royal Devon & Exeter NHS Foundation Trust (GB)
- University Hospitals Bristol NHS Foundation Trust (GB)
- Gloucestershire Hospitals NHS Foundation Trust (GB)
- University of Bristol (GB)
- Taunton & Somerset NHS Foundation Trust (GB)
- Royal United Hospital Bath NHS Trust (GB)
- Institute of Infection and Immunity (CA)
- Somerset NHS Foundation Trust
- Cardiff University (GB)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.esmorw.2024.100064
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.68
Funders
- Wellcome Trust